- Jaguar Animal Health (JAGX +1.5%) inches up modestly higher volume after an announcement by planned merger partner Napo Pharmaceuticals about HIV-related diarrhea product Mytesi (crofelemer).
- A supplemental analysis of a long-term study showed treatment with Mytesi lowered the average number of diarrhea episodes in HIV patients 70% from baseline with half completely resolving their diarrhea. The data were presented at the 9th IAS Conference on HIV Science in Paris.
- Napo launched Mytesi in October 2016. Crofelemer is also the active ingredient in Jaguar's Canalevia for the treatment of acute diarrhea in dogs.
- Previously: Jaguar Animal Health to merge with Napo Pharmaceuticals (Feb. 8)
- Previously: Jaguar Animal Health's lead product candidate shows statistically valid effect in proof-of-concept study; shares ahead 5% (Oct. 18, 2016)
- Now read: Ad Com approaches for Intellipharmaceutics' marketing application for abuse-deterrent extended-release oxycodone; shares off 10% as investors digest briefing docs
Original article